Harvard Bioscience SEC Filings

Type
Report
Date
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/10/2026
424B3424B3-Formular2/9/2026
DEF 14ADEF 14A-Formular1/30/2026
S-3S-3-Formular1/30/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/29/2026
PRE 14APRE 14A-Formular1/20/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/20/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/12/2026
4Insidertransaktion12/30/2025
33-Formular12/30/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/17/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/5/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/6/2025
10-QQuartalsbericht11/6/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/3/2025
4Insidertransaktion10/7/2025
33-Formular10/7/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/3/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/9/2025
4Insidertransaktion8/19/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/13/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/11/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/11/2025
4Insidertransaktion8/11/2025
10-QQuartalsbericht8/11/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular8/7/2025
33-Formular7/25/2025
4Insidertransaktion7/25/2025
4Insidertransaktion7/18/2025
4Insidertransaktion7/18/2025
33-Formular7/18/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/17/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular7/17/2025
8-K/A8-K/A-Formular6/27/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/23/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/13/2025
33-Formular6/9/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/2/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/30/2025
SDSD-Formular5/27/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/15/2025
4Insidertransaktion5/14/2025
33-Formular5/14/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/14/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/12/2025
10-QQuartalsbericht5/12/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/8/2025
ARSARS-Formular4/22/2025
DEF 14ADEF 14A-Formular4/21/2025
DEFA14ADEFA14A-Formular4/21/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/16/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/10/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4/8/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4/7/2025
4Insidertransaktion3/21/2025
4Insidertransaktion3/21/2025
SCHEDULE 13GSCHEDULE 13G-Formular3/17/2025
10-KJahresbericht3/14/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/12/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/12/2025
SCHEDULE 13GSCHEDULE 13G-Formular2/10/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular2/4/2025
4Insidertransaktion1/3/2025
4Insidertransaktion12/31/2024
4Insidertransaktion12/31/2024
S-3S-3-Formular12/6/2024
SC 13G/ABeneficial ownership report11/14/2024
10-QQuartalsbericht11/8/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/7/2024
10-QQuartalsbericht8/8/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/8/2024
4Insidertransaktion6/14/2024
4Insidertransaktion6/7/2024
SDSD-Formular5/29/2024
4Insidertransaktion5/23/2024
4Insidertransaktion5/23/2024
4Insidertransaktion5/23/2024
4Insidertransaktion5/23/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/14/2024
10-QQuartalsbericht5/7/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/7/2024
ARSARS-Formular4/3/2024
DEFA14ADEFA14A-Formular4/3/2024
DEF 14ADEF 14A-Formular4/3/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/3/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/26/2024
SC 13GSC 13G-Formular3/19/2024
4Insidertransaktion3/7/2024
4Insidertransaktion3/7/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/7/2024
10-KJahresbericht3/7/2024
SC 13G/ABeneficial ownership report2/14/2024
SC 13G/ABeneficial ownership report2/14/2024
SC 13G/ABeneficial ownership report2/14/2024
SC 13G/ABeneficial ownership report2/13/2024
SC 13GSC 13G-Formular1/26/2024
SC 13G/ABeneficial ownership report1/22/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/5/2024
4Insidertransaktion1/3/2024
4Insidertransaktion1/3/2024

Harvard Bioscience Documents 2026

This page contains all official documents and SEC filings for Harvard Bioscience stock (HBIO, ISIN: US4169061052). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Harvard Bioscience's regulatory filings.

Harvard Bioscience Stock analysis

Harvard Bioscience Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world.